Predictors of erythropoietin responsiveness in chronic hemodialysis patients

ASAIO Journal

Volumn 47, Issue 1, 2001, Pages 82-85

  Tonelli, Marcello ^a,c   Blake, Peter G ^b   Muirhead, Norman ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CALCIUM ION; ERYTHROPOIETIN; HEMOGLOBIN; IRON; IRON DEXTRAN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADOLESCENT; ADULT; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEMATOCRIT; HEMODIALYSIS; HUMAN; IRON BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREDICTION; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME;

EID: 0035191135     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002480-200101000-00017     Document Type: Article

References (23)

1. Erythropoietin hyporesponsiveness: From iron deficiency to iron overload
2. NKF-DOQI: Clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative
3. Modulating factors in the hematopoietic response to erythropoietin
4. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients
5. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease
6. Anemia in hemodialysis patients: Variables affecting this outcome predictor
7. Hemodialysis trends in time, 1989 to 1998, independent of dose and outcome
8. Status of hemodialysis adequacy in the United States: Does it account for improved patient survival?
9. Hematopoietic inhibitors in chronic renal failure: Lack of in vitro specificity
10. The anemia of end-stage renal disease: Hematopoietic progenitor cell response
11. Uremic inhibitors of erythropoiesis
12. Erythropoiesis in patients with renal failure undergoing chronic dialysis
13. Improving anemia by hemodialysis: Effect of serum erythropoietin
14. Erythropoietin in the pathogenesis and treatment of the anemia of chronic renal failure [Editorial]
15. Inhibition of erythrocyte aminolevulinate dehydratase by a 56.2-kD peptide from uremic plasma
16. Disorders of iron metabolism in the uremic patient
17. Impaired biological activity of erythropoietin by cyanate carbamylation
18. Dialysis dose, membrane type, and anemia control
19. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients
20. Determinants of albumin concentration in hemodialysis patients
21. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia
22. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: Any evidence of erythropoietin resistance?
23. Angiotensin-converting enzyme inhibitors and higher erythropoietin requirement in chronic haemodialysis patients